I'm LongbridgeAI, I can summarize articles.ADC Therapeutics presented Phase 3 LOTIS-5 data for Zynlonta plus rituximab in relapsed/refractory DLBCL. The trial met its primary endpoint, showing improved progression-free survival (HR 0.73) and higher response rates compared to rituximab alone. While overall survival was comparable, the combination therapy showed increased adverse events, including higher grade 5 TEAEs and withdrawal rates.
- ADC Therapeutics highlighted Phase 3 LOTIS-5 data for ZYNLONTA plus rituximab in 2L+ relapsed or refractory DLBCL. * Trial met primary endpoint: PFS by independent review HR 0.73; p 0.0084; median PFS 6.14 months vs 4.73 months. * IRC overall response 58% vs 45%; complete response 40% vs 27%; median duration of complete response 16.82 months vs 12.25 months. * Overall survival showed no detriment: HR 0.96; median OS 12.19 months vs 12.16 months. * Grade 5 TEAEs 13.2% vs 4.6%; serious TEAEs 49% vs 34.5%; withdrawals 25.5% vs 9.1%. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADC Therapeutics SA published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here